Regentis reports surgeon interest in GelrinC at ICRS Summit in Portugal

Regentis Biomaterials Ltd. (NYSE American: RGNT) said on October 12, 2026 that it saw strong engagement from orthopedic surgeons and cartilage repair specialists at its booth during the 8th International Cartilage Regeneration & Joint Preservation Society Summit, held October 8–10, 2026, in Porto, Portugal¹.

Booth conversations centered on GelrinC, the company's CE Mark-approved, cell-free hydrogel implant designed to regenerate damaged knee cartilage¹. Representatives discussed the product's clinical results, ready-to-use design, and potential to simplify cartilage repair versus traditional surgery¹. The company noted that GelrinC is administered in one procedure lasting about 10 minutes and does not require harvesting cells or lab processing beforehand¹. Citing its Phase II study, Regentis said patients treated with GelrinC saw roughly double the improvement in overall KOOS scores at two years compared with historical microfracture controls, with later MRI findings consistent with durable, native-like cartilage regrowth¹.

CEO and Executive Chairman Ehud Geller said the quality of surgeon interactions at ICRS was encouraging¹ and added that with GelrinC already CE Mark approved in Europe, the company is working to turn physician interest into broader adoption, while its European clinical sites also feed into the ongoing U.S. FDA pivotal trial, giving more surgeons exposure to the product¹.

Regentis said the pivotal U.S. FDA study has passed the halfway point in enrollment¹. The company also said it believes GelrinC could serve roughly 470,000 annual U.S. cases of knee cartilage repair, a market it says currently lacks an off-the-shelf option¹.